HLA-A and chronic myelogenous leukemia, BCR-ABL1 positive: To determine specific CD8+ T cell responses to eLAAs (Table 2) and pLAAs HLA-I peptides (Table 1), PBMCs from 4 HLA-A*02:01 healthy donors and 8 HLA-A*02:01 CML patients in chronic stage were stimulated for 7 days with the individual peptides with IL-2 addition at day 1 and 3, and analyzed for epitope-specific T cells by INFγ ELISpot assays as detailed in materials and methods.